FOA No. Title OrgRelease/Open Dates Exp. Date Activity Code(s) No. Awards Amount Comments
HRSA-20-014Opioid-Impacted Family Support ProgramRelease Date:
Open Date:
19
TI-20-006SAMHSARelease Date: 01/17/2020
Open Date: 01/17/2020
03/17/20202$850,000/year
TI-20-0092020 Rural Opioid Technical Assistance GrantsSAMHSARelease Date: 03/09/2020
Open Date: 03/09/2020
05/08/20205$550,000

The purpose of this program is to develop and disseminate training and technical assistance for rural communities on addressing opioid issues affecting these communities. It is expected that recipients will facilitate the identification of model programs, develop and update materials related to the prevention, treatment, and recovery activities for opioid use disorder (OUD), and ensure that high-quality training is provided.

TI-20-0112020 Tribal Opioid Response grantsSAMHSARelease Date: 03/03/2020
Open Date: 03/03/2020
05/04/2020200$1,800,000
PAR-18-362Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)NIDA and NIAAARelease Date: 09/09/2019
Open Date: 09/05/2019
09/08/2021R01Contingent upon appropriationsUp to $499,999 directs/year

Up to 5 year project period
Reissue of PAR-18-362

Related Notices
NOT-OD-19-128, Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research
NOT-OD-19-137, Clarifying Competing Application Instructions and Notice of Publication of Frequently Asked Questions (FAQs) Regarding Proposed Human Fetal Tissue Research.

PAR-18-747Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R01 Clinical Trial Optional)NIMHDRelease Date: 04/10/2018
Open Date: 05/15/2018
11/14/2020R01Not limited
PAR-18-745Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional)NIMHDRelease Date: 04/10/2018
Open Date: 05/15/2018
11/14/2020R21$275K for 2 years
PA-18-591Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)NIHRelease Date: 01/25/2018
Open Date: 01/25/2018
01/26/2021
RFA-DA-18-022Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01  Clinical Trial Optional)NIDARelease Date: 03/14/2018
Open Date: 07/22/2018
08/22/2020R013 to 4
PAR-19-207Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)NIAAA/NIDARelease Date: 03/04/2019
Open Date: 04/25/2019
09/08/2022R25not limitedNot limited
PAR-19-207Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed)NIAAA/NIDARelease Date: 03/04/2019
Open Date: 04/25/2019
09/08/2022R01Not limited
RFA-NS-18-046Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)NINDSRelease Date: 09/19/2018
Open Date: 10/27/2018
03/13/2020R61/R338 to 10Not limited
PA-18-945Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R01 Clinical Trial Optional)NINRRelease Date: 10/01/2018
Open Date: 01/05/2019
01/08/2022R01Not limited
PA-18-946Applying a Biopsychosocial Perspective to Self-Management of Chronic Pain (R21 Clinical Trial Optional)NINRRelease Date: 10/01/2018
Open Date: 01/16/2018
01/08/2022R21$275K for 2 years
PAR-20-225Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)Release Date: 06/01/2020
Open Date: 09/19/2020
10/20/2022DP1Contingent upon appropriations$300,000
PAR-19-223Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)NIDARelease Date: 03/18/2019
Open Date: 09/21/2019
10/20/2021$up to 300K for up to 5 years
PAR-20-224Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)Release Date: 06/01/2020
Open Date: 07/13/2020
08/16/2020DP2$375,000
PA-18-944Biobehavioral Basis of Chronic Pain (R01 Clinical Trial Optional)NINRRelease Date: 10/01/2018
Open Date: 01/05/2018
01/08/2022R01Not limited
PA-18-943Biobehavioral Basis of Chronic Pain (R21 Clinical Trial Optional)NINRRelease Date: 10/01/2018
Open Date: 01/16/2018
01/08/2022R21$275K for 2 years
PAR-19-158Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)MultiRelease Date: 01/08/2019
Open Date: 01/08/2019
01/08/2022R01Not limited

Translational group

PAR-19-159Bioengineering Research Grants (BRG) (R01 Clinical Trial Required)MultiRelease Date: 01/08/2019
Open Date: 01/08/2019
05/08/2021R01Not limited

Translational group

PAR-19-156Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed)MultiRelease Date: 01/08/2019
Open Date: 01/08/2019
01/08/2022U01Not limited

Translational group

PAR-19-157Bioengineering Research Partnerships (U01 Clinical Trial Required)MultiRelease Date: 01/08/2019
Open Date: 01/08/2019
01/08/2022U01Not limited

Translational group

BJA-2019-15111BJA FY 19 Comprehensive Opioid Abuse Site-based ProgramDOJRelease Date: 04/05/2019
Open Date:
150Up to $5M
BJA-2020-17023BJA FY 20 Comprehensive Opioid, Stimulant, and Substance Abuse Site-based Program (COSSAP)Department of Justice Bureau of Justice AssistanceRelease Date: 02/21/2020
Open Date: 02/21/2020
05/21/2020120$6,000,000
BJA-2020-17754BJA FY 20 Harold Rogers Prescription Drug Monitoring Program (PDMP)Department of Justice Bureau of Justice AssistanceRelease Date: 03/06/2020
Open Date:
03/05/202014$2,000,000
BJA-2020-17106BJA FY 20 Improving Reentry for Adults with Substance Use Disorders ProgramDepartment of Justice Bureau of Justice AssistanceRelease Date: 02/26/2020
Open Date:
04/27/202014$900,000 ceiling
NOT-NS-20-044Clinical Research in Pain ManagementHEALRelease Date: 06/01/2020
Open Date: 05/15/2020
07/31/2020DP1Contingent upon appropriations$50.000

Related Announcements
PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

PAR-20-237Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)Release Date: 06/17/2020
Open Date: 07/28/2020
12/02/2020R01Contingent upon NIH appropriations$500,000/year
HHS-2020-IHS-COIPP-0001Community Opioid Intervention Pilot ProjectDepartment of Health and Human ServicesRelease Date: 02/14/2020
Open Date:

Forecasted

PAR-20-092Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)NIDARelease Date: 01/24/2020
Open Date: 01/24/2020
09/02/2022UG3/UH3The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.$3M/year in directs
RFA-DA-19-002Development of Medications to Prevent and Treat Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)NIDARelease Date: 12/14/2017
Open Date: 01/25/2018
02/23/2020UG3/UH33 to 4Total $10M/Fiscal year
BAA-DAIT-75N93019R00009Development of Vaccines for the Treatment of Opioid Use DisorderNIAIDRelease Date: 03/05/2019
Open Date:
$2-3M/year
PAR-20-279Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)NIDA/NIAAARelease Date: 07/27/2020
Open Date: 11/15/2020
08/11/2023UG3/UH3Contingent upon meritorious applications$500K per year
EDSUSS-2020Device-Based Treatments for Substance Use Disorders (UG3/UH3, Clinical Trial Optional)The Office of National Drug Control Policy (ONDCP)Release Date: 08/14/2020
Open Date: 08/14/2020
09/14/2020$300K

This project seeks to further refine and geographically expand a methodology for obtaining drug early warning indicators through broader testing of urine samples that were previously collected and tested as part of an existing drug test protocol. This method was initially developed using local criminal justice populations – including persons in pre-trial or lock-up, parolees or probationers, and drug court participants. Similar methodology is promising for use in other venues, such as in trauma units and emergency departments, where biological samples are often collected from patients. Before the specimens are discarded, the project will re-test them for an expanded panel of drugs, including synthetic cannabinoids, to determine what old and new illicit drugs are detected or missed by conventional testing protocols, and how the drug patterns might vary by subpopulation and geography. Bypassing the expense of collecting the original specimens and re-using those that have already been tested with known results yields a relatively inexpensive and timely picture of emerging drugs in a given subpopulation and locality. ONDCP is seeking to apply this testing methodology to Emergency Department populations in locations throughout the United States.

PA-17-120Discovering Novel Targets: The Molecular Genetics of Drug Addiction and Related Co-Morbidities (R01)NIDARelease Date: 01/10/2017
Open Date: 01/10/2017
01/08/2020R01Not limited
RFA-NS-18-041Discovery of Biomarkers, Biomarker Signatures, and Endpoints for Pain (R61/R33 Clinical Trial Optional)NINDSRelease Date: 08/02/2018
Open Date: 10/27/2018
03/13/2020R61/R338 to 10Not limited
SP-19-006Drug-Free Communities (DFC) Support Program-Competing ContinuationDFCRelease Date:
Open Date:
CDC-RFA-CE20-2002Drug-Free Communities (DFC) Support Program-NewCDCRelease Date: 02/18/2020
Open Date:
06/08/2020200$125,000
SP-19-005Drug-Free Communities (DFC) Support Program-NewDFCRelease Date:
Open Date:
CDC-RFA-CE20-2002Drug-Free Communities (DFC) Support Program-New Department of Health and Human Services Centers for Disease Control - NCIPCCDCRelease Date: 02/18/2020
Open Date: 02/18/2020
06/08/2020200$125,000
NOT-NS-20-023Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-18-906 Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)HEALRelease Date: 03/03/2020
Open Date: 04/15/2020
06/30/2020Contingent upon appropriations$50.000

Related Announcements
PA-18-906 - Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

PAR-19-278Exploiting Genome or Epigenome Editing to Functionally Validate Genes or Variants Involved in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)NIDARelease Date: 05/08/2019
Open Date: 05/24/2019
12/18/2021R21/R33R21 - Not to exceed $125K/year. R33-Not to exceed $250K
RFA-DA-20-019Exploiting In Vivo Precision Pharmacology Techniques to Understand Opioid Receptor Signaling in Specific Circuits, Cell Types, and Subcellular Compartments (R61/R33 - Clinical Trial Not Allowed)NIDARelease Date: 05/30/2019
Open Date: 09/17/2019
R61/R335Up to $300K
PAR-19-282Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)NIDARelease Date: 05/15/2019
Open Date: 09/10/2019
05/08/2023R61/R33ContingentSee announcement
FOR-FD-20-008FOR-FD-20-008Food and Drug AdministrationRelease Date:
Open Date: 03/06/2020

Forecasted

PA-FPR-19-001FORECASTED: Availability of funds for Title X Family Planning– Innovations in Family Planning Clinical Service Delivery and Studies to Address Opportunities and Barriers for Linking Family Planning Services and Substance Use Disorder Screening and TreatmentDHHS/OASHRelease Date:
Open Date:
10$400K
PA-17-155Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R01)NIDARelease Date: 02/08/2017
Open Date: 05/05/2017
05/08/2020R01Not limited
PA-17-157Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders (R21)NIDARelease Date: 02/08/2017
Open Date: 05/16/2017
05/08/2020R21$275K for 2 years
PAR-19-327Grand Opportunity in Medications Development for Substance-Use Disorders (U01 - Clinical Trial Optional)NIDARelease Date: 08/01/2019
Open Date: 07/26/2019
09/02/2022U01three to fourUp to $5M/year
RFA-DA-19-020HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R41/R42 - Clinical Trial Optional)NIDARelease Date: 12/10/2018
Open Date: 01/10/2019
09/09/2021R41/R423 to 10Total $3M FY2019
RFA-DA-19-019HEAL Initiative: Americas Startups and Small Businesses Build Technologies to Stop the Opioid Epidemic (R43/R44 - Clinical Trial Optional)NIDARelease Date: 12/10/2018
Open Date: 12/10/2018
09/09/2021R43/R4410 to 30Total $7M FY2019
RFA-NS-19-018HEAL Initiative: Clinical Devices to Treat Pain (UH3 Clinical Trial Optional)NINDSRelease Date: 12/10/2018
Open Date: 12/10/2018
02/23/2021UH33 to 4Total $3M
RFA-HL-20-031HEAL Initiative: Pharmacotherapies to Reverse Opioid Overdose Induced Respiratory Depression without Central Opioid Withdrawal (Target Validation and Candidate Therapeutic Development (R61/R33 - Clinical Trial Not Allowed) Department of Health and Human ServicesNIHRelease Date: 01/24/2020
Open Date: 01/24/2020
03/24/2020R61/R33

NHLBI intends to commit total costs of up to $7,000,000 in FY2020-2021 to fund up to 10Phase I (R61) awards.

NHLBI intends to commit total costs of up to $3,000,000 per year in FY2022-2024 to fund up to 5 Phase II (R33) awards.

RFA-AT-20-004HEAL Initiative: Pragmatic and Implementation Studies for the Management of Pain to Reduce Opioid Prescribing (PRISM) (UG3/UH3, Clinical Trials Optional)NIHRelease Date: 01/23/2020
Open Date: 02/29/2020
03/31/2020UG3/UH31-2

The application budget for the UG3 phase is limited to $500,000/year in direct costs. Costs for each year of the UH3 phase are limited to $1 million/year in direct costs.

RFA-EB-18-003HEAL Initiative: Translational Development of Devices to Treat Pain (U18 Clinical Trial Not Allowed)NIBIBRelease Date: 12/10/2018
Open Date: 01/08/2019
02/23/2021U185 to 10Not to exceed $500K
RFA-NS-19-017HEAL Initiative: Translational Devices to Treat Pain (U44 Clinical Trial Optional)NINDSRelease Date: 12/10/2018
Open Date: 12/10/2018
02/23/2021U444 to 8Not to exceed $1M/year in Phase 1
RFA-NS-19-016HEAL Initiative: Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)NINDSRelease Date: 12/10/2018
Open Date: 12/09/2018
02/23/2021UG3/UH33 to 6Total $4M
RFA-FD-20-031Incorporating cost effectiveness & societal outcomes into FDA opioids model (U01) Clinical Trials Not AllowedFDARelease Date: 03/13/2020
Open Date: 03/16/2020
05/19/2020U01The number of awards is contingent upon FDA appropriations and the submission of a sufficient number of meritorious applications. Award(s) will provide one (1) year of support.1,000,000
PAR-20-035Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)NIDA, NCI, NIAAARelease Date: 10/18/2019
Open Date: 02/17/2020
11/08/2022R61/R33Contingent upon appropriationsUp to $300,000
PAR-20-182Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)NIDARelease Date: 05/04/2020
Open Date: 09/30/2020
10/31/2020R011-3Less than $1M/year for upt ot 5 years
PAR-20-241Large scale mapping and/or molecular profiling of ensembles and/or cell-types mediating opioid action in the rodent brain (R01 - Clinical Trial Not Allowed)NIDARelease Date: 06/24/2020
Open Date: 09/30/2020
10/31/2020R011-3$1M
PAR-19-099Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award, (U01 Clinical Trial Optional)NCATSRelease Date: 12/12/2018
Open Date: 02/08/2019
11/10/2021U01Clinical not to exceed $750K. Non-clinical not to exceed $400K
PAR-19-100Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)NCATSRelease Date: 12/12/2018
Open Date: 02/08/2019
11/10/2021R21Not to exceed $200K
PA-18-061Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R01 Clinical Trial Optional)NIDA/NIARelease Date: 11/03/2017
Open Date: 01/06/2018
05/08/2020R01Not limited
PA-18-079Marijuana, Prescription Opioid, or Prescription Benzodiazepine Drug Use Among Older Adults (R21 Clinical Trial Optional)NIDA/NIARelease Date: 11/03/2017
Open Date: 01/17/2018
05/08/2020R21$275K for 2 years
PAR-19-064Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)NIDARelease Date: 11/09/2019
Open Date: 01/08/2019
11/09/2021R21$275K for 2 years
PA-19-200Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R01 Clinical Trial Optional)NIHRelease Date: 02/28/2019
Open Date: 05/05/2019
07/08/2022R01Not limited
PA-19-201Mechanisms Underlying the Contribution of Sleep Disturbances to Pain (R21 Clinical Trial Optional)NIHRelease Date: 02/28/2019
Open Date: 05/16/2019
07/08/2022R21$275K/2 years
PAS-18-625Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)NIDARelease Date: 02/02/2018
Open Date: 05/16/2018
09/08/2020R213 to 5Total $2M for FY2019
PAS-18-625Mechanistic investigations of psychosocial stress effects on opioid use patterns (R21- Clinical Trial Optional)NIDARelease Date: 02/02/2018
Open Date: 05/16/2018
09/08/2020R213 to 5$275K total project
PAR-20-119National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders, Substance Use Disorders, or Alcohol Use Disorder (U19 Clinical Trial Optional)NIHRelease Date: 02/25/2020
Open Date: 06/27/2020
03/26/2022U19The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.Application budgets are not limited but need to reflect the actual needs of the proposed project.
PAR-20-118National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Disorder (U01 Clinical Trial Optional)NIHRelease Date: 02/25/2020
Open Date: 06/27/2020
03/26/2022U01The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.Application budgets are not limited but need to reflect the actual needs of the proposed project.
NOT-TR-20-025NCATS Announces Plans to Publish the ASPIRE 2020 Reduction-to-Practice Challenge Prize CompetitionNCATSRelease Date: 08/26/2020
Open Date:

In this Reduction-to-Practice Challenge, the second phase of the initiative, NCATS aims to build upon the designs from the Design Challenges and reward the development of a working prototype of a comprehensive integrated platform, culminating in the development of better, more effective and non-addictive analgesics. It is anticipated that this Challenge would require large, multi-expert teams. These teams may be assembled from the innovators from the 2018 Design Challenge areas and others who did not participate in the 2018 Design Challenges. This Notice alerts the scientific community that NCATS intends to hold a three-stage prize open competition for the NCATS ASPIRE Reduction-to-Practice Challenge, the stages are 1) planning, 2) prototype development and milestones delivery, and 3) prototype delivery and validation and testing. It is anticipated that the announcement will be published in September 2020, with the submission window for Stage 1 planning solutions from late November through the end of February 2021.

PA-18-078Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)NIDARelease Date: 11/03/2017
Open Date: 01/17/2018
01/08/2020R21$275K for 2 years
PAR-20-221NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1, Clinical Trial Optional)NIDARelease Date: 06/01/2020
Open Date: 07/13/2020
08/16/2022DP12-3 awards/year$700,000

Reissue of RFA-DA-18-019

PAR-20-267NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)NIDARelease Date: 07/17/2020
Open Date: 08/25/2020
11/18/2022P30Contingent upon meritorious applicationsNot limited
PAR-20-249NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)NIDARelease Date: 07/01/2020
Open Date: 02/01/2021
11/16/2023K12Contingent upon NIH appropriations$500K/year
PAR-20-249NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)NIDARelease Date: 07/01/2020
Open Date: 02/01/2021
11/16/2023K12Contingent upon meritorious applications$500K per year
PAR-18-746NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)NIDARelease Date: 04/06/2018
Open Date: 05/11/2018
08/29/2020K12$500K Direct costs/year
RFA-DA-18-020NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)NIDARelease Date: 12/06/2018
Open Date: 06/25/2019
07/26/2020UG3/UH3Up to 2/yearTotal $2M FY2019
NOT-DA-20-062Notice of Clarification to PAR-19-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)"NIDARelease Date: 06/11/2020
Open Date:

The purpose of this Notice is to inform potential applicants that the National Institute on Drug Abuse is adding a priority area focused on policy-relevant research and researcher-practitioner partnerships to PAR-19-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional).

NOT-DA-19-035Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)NIDARelease Date:
Open Date:
NOT-DA-20-044Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)DHHS/NIHRelease Date: 04/06/2020
Open Date: 05/01/2020
07/13/2020$700,000
NOT-HS-20-001Notice of Intent to Publish Funding Opportunity Announcement to Improve the Management of Opioids and Opioid Use Disorder in Older AdultsAHRQRelease Date: 10/25/2019
Open Date:
NOT-AA-19-020Notice of NIAAA Data-Sharing Policy for Human Subjects Grants Research Funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) [2nd Revision]NIAARelease Date: 07/31/2019
Open Date:

Several FOA's affected by this notice

NOT-MD-20-019Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health DisparitiesNIMHD, NIA, NIMHRelease Date: 04/10/2020
Open Date: 05/01/2020
05/01/2021P20125,000
NOT-DA-19-066Notice of Special Interest (NOSI): Epidemiology of Drug AbuseNIDARelease Date: 08/29/2019
Open Date: 10/05/2019
01/08/2022
NOT-DA-19-38Notice of Special Interest (NOSI): Gene-Environment Interplay in Substance Use Disorders (R01, R21)Release Date:
Open Date:
NOT-DA-19-037Notice of Special Interest (NOSI): Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (R01, R21, R03)Release Date:
Open Date:
NOT-DA-20-009Notice of Special Interest (NOSI): Modeling Social Contagion of Substance Use EpidemicsNIDARelease Date: 01/02/2020
Open Date: 01/02/2020
01/28/2023

The purpose of this Notice is to inform potential applicants to the National Institute on Drug Abuse (NIDA) of special interest in research projects involving the application of social network theory to study the social contagion of behaviors associated with substance use disorders that can provide insight into the prediction and prevention of the contagion of substance use epidemics. Applications should make use of large data sets and data science approaches to develop computational models of social networks to examine the association between social influence and substance use/misuse among individuals and their peers.

NOT-DA-20-004Notice of Special Interest (NOSI): Research on Co-morbid Substance Use, Substance Use Disorders, and Other Psychiatric DisordersNIDARelease Date:
Open Date:
05/08/2023

The association between substance use, substance use disorders, and psychiatric disorders, including depression, anxiety, bipolar disorder, ADHD and other externalizing disorders, has been well established through population based epidemiologic surveys. Numerous developmentally focused theory-based approaches have been proposed, including shared underlying vulnerabilities or risk factors. From a disorder perspective, prevalence can be expressed as either the prevalence of other psychiatric disorders among substance using populations or the prevalence of substance use among individuals with other psychiatric disorders, leading to variability in rates. Mental illness is often characterized as a risk factor for substance use initiation and for transition from use to misuse and disorder, though the exact sequence and relationship between substance use, substance use disorders and psychiatric co-morbidity is unclear and may vary by disorder. For some substances and disorders, it may be the substance use that precedes the onset of other psychiatric symptoms. Additional research is needed to determine the various trajectories of substance use and psychiatric symptoms, as well as strategies for intervention to change trajectories.

NOT-DA-19-048Notice of Special Interest (NOSI): Research to Prevent Drug Use, Misuse and AddictionRelease Date:
Open Date:
NOT-DA-20-060Notice of Special Interest (NOSI): Role of Astrocytes and Astrocytic Networks in Drug AbuseNIDARelease Date: 06/01/2020
Open Date: 10/05/2020
09/08/2023

The purpose of this Notice is to inform potential applicants of NIDA’s interest in research project grant submissions that examine the effects of drugs of abuse on the function and functional roles of astrocytes, the structural connectivity of astrocytic networks, the generation, processing and spatiotemporal control of astrocytic activity within these networks, and the consequent effects of changes in astrocyte activity due to drugs of abuse on neuronal structure and function.

NOT-DA-19-041Notice of Special Interest (NOSI): The Application of Big Data Analytics to Drug Abuse ResearchRelease Date:
Open Date:
NOT-TR-20-008Notice of Special Interest for HEAL Initiative: Request for Administrative Supplements to Existing Grants for Identification and Validation of New Pain and Opioid Use Disorder Targets within the Understudied Druggable GenomeNCATS, NIDCR, NIDA, NINDS, NCCIHRelease Date: 03/09/2020
Open Date: 03/17/2020
06/02/2020Not to exceed $99,999

This Notice is part of the NIH Helping to End Addiction Long-Term (HEAL) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.

NCATS and other participating institutes and Centers (ICs) are inviting investigators with relevant active research project grants and cooperative agreements to submit administrative supplements, according to PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional), for funded projects to identify and validate new pain and opioid use disorder (OUD) targets from within the understudied Druggable Genome.

RFA-DA-21-024PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)NIDA/NIAIDRelease Date: 06/29/2020
Open Date: 10/12/2020
11/13/2020R012-3$2.5M over 5 years
RFA-DA-21-024PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)NIDA, NIAIDRelease Date: 06/29/2020
Open Date: 10/12/2020
11/13/2020R012-3Not limited
PA-17-134Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R03)NIAAARelease Date: 01/25/2017
Open Date: 05/16/2017
05/08/2020R03$50K/year
PA-17-132Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes (R21)NIAAARelease Date: 01/25/2017
Open Date: 05/16/2017
05/08/2020R21$275K for 2 years
 FOA No. Title OrgRelease/Open Dates Exp. Date Activity Code(s) No. Awards Amount Comments